Neuroleptic malignant syndrome

T. J. Ingall, C. Tennant

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

The neuroleptic malignant syndrome is a relatively rare but potentially fatal complication of the use of major tranquilizers; mortality may be as high as 20%. The syndrome is manifest by the onset of hyperpyrexia, muscular rigidity and tremor, impaired consciousness and autonomic dysfunction. The pathophysiology is thought to be by way of dopamine receptor blockade. The syndrome is managed by cessation of the neuroleptic medication, by supportive measures and by instituting treatment with one or more of a number of specific drugs whose use is based on theoretical considerations rather than empirical evidence of efficacy; these drugs include anticholinergics, L-dopa, bromocriptine amantidine and dantrolene sodium. Although not proven, early recognition and treatment may reduce both the mortality and the longer term morbidity of this syndrome.

Original languageEnglish (US)
Pages (from-to)454-455
Number of pages2
JournalMedical Journal of Australia
Volume145
Issue number9
DOIs
StatePublished - 1986

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Neuroleptic malignant syndrome'. Together they form a unique fingerprint.

  • Cite this